Compare AstraZeneca plc (AZN) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares Russell 2000 ETF — how do they compare? AstraZeneca plc trades at $158.61 (market cap $248.14B), while iShares Russell 2000 ETF trades at $303.19. The key difference: AstraZeneca plc pays a 2.01% dividend while iShares Russell 2000 ETF pays none, and iShares Russell 2000 ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | IWM | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | — |
52-Week High | $209.48 | $302.71 |
52-Week Low | $147.06 | $225.45 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
IWM (iShares Russell 2000 ETF) trades at $302.71, up 0.91% with a bullish technical signal from moving averages. The ETF, tracking 2,000 US small-cap stocks, shows strong institutional interest despite lacking traditional valuation ratios. Recent news highlights small-cap outperformance versus large caps, with institutional investors favoring IWM for its liquidity and options ecosystem. Technical indicators show RSI at 75 suggesting overbought conditions while ADX indicates a strong trend.
Outlook remains positive as small caps benefit from economic conditions, though high RSI suggests near-term consolidation risk. The ETF's broad small-cap exposure offers diversification but faces volatility from economic sensitivity. Institutional accumulation supports medium-term upside potential despite premium valuation concerns versus alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
